Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

96
Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
96
Esophageal Varices-I: Introduction01:24

Esophageal Varices-I: Introduction

183
Esophageal varices are dilated, tortuous veins which are found mainly in the submucosa of the lower esophagus but which may also appear higher up or extend into the stomach. They develop due to increased pressure in the portal venous system, often as a result of liver cirrhosis. This condition scars and damages the liver, impeding normal blood flow through the portal vein. To compensate, blood seeks alternative pathways, forming fragile new vessels (varices) in the esophagus and stomach. These...
183
Vascular Spasm01:16

Vascular Spasm

1.5K
The vascular phase, also known as vasospasm, is the initial stage of hemostasis, crucial for preventing excessive bleeding when a blood vessel is injured. After a vessel is cut, nerves in the damaged area trigger pain and other sensory impulses. Simultaneously, the smooth muscles in the vessel wall contract, resulting in a vascular spasm. This contraction reduces the vessel's diameter at the injury site, slowing or stopping blood loss through the vessel wall. Vascular spasms typically last...
1.5K
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation01:30

Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation

193
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
193
Nephrotic Syndrome I : Introduction01:24

Nephrotic Syndrome I : Introduction

9
Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of...
9
Nephrotic Syndrome II : Assessment and Medical Management01:26

Nephrotic Syndrome II : Assessment and Medical Management

8
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
8

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Distinct clinical, molecular, and treatment response profiles in primary and secondary myelofibrosis: a single-center retrospective study.

Hematology (Amsterdam, Netherlands)·2026
Same author

A survival prognostic model for high-risk myelodysplastic syndrome patients treated with decitabine.

Hematology (Amsterdam, Netherlands)·2026
Same author

Rapamycin and Cyclosporin A Alleviate Bone Marrow Adiposity in Murine Model of Aplastic Anemia.

Clinical laboratory·2026
Same author

Somatic Mutations and Mutation Burden Predict Treatment Response and Survival in Adult Acquired Pure Red Cell Aplasia.

American journal of hematology·2026
Same author

Immune-Mediated Multilineage Cytopenias in Thymoma: A Retrospective Case Series.

Thoracic cancer·2026
Same author

The Immunoregulatory and Hematopoietic Effects of Momelotinib in a Murine Bone Marrow Failure Model.

Journal of clinical laboratory analysis·2026

Related Experiment Video

Updated: Jul 21, 2025

Demystifying Venous Excess Ultrasound (VExUS): Image Acquisition and Interpretation
05:49

Demystifying Venous Excess Ultrasound (VExUS): Image Acquisition and Interpretation

Published on: May 16, 2025

895

VEXAS Syndrome-Review.

Yue Zhang1, Xifeng Dong1, Huaquan Wang1

  • 1Department of Hematology, General Hospital, Tianjin Medical University, Tianjin, China.

Global Medical Genetics
|July 28, 2023
PubMed
Summary

VEXAS syndrome, an adult-onset autoinflammatory condition, stems from somatic UBA1 gene mutations. This newly defined syndrome presents with severe systemic inflammation and hematologic issues, requiring urgent physician attention.

Keywords:
UBA1VEXAS syndromeautoinflammatoryhematological disordersvacuoles

More Related Videos

Echocardiographic Assessment Using Subxiphoid-Only Examination for Hypotensive Patients
08:37

Echocardiographic Assessment Using Subxiphoid-Only Examination for Hypotensive Patients

Published on: April 18, 2025

356
Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
04:29

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

28.7K

Related Experiment Videos

Last Updated: Jul 21, 2025

Demystifying Venous Excess Ultrasound (VExUS): Image Acquisition and Interpretation
05:49

Demystifying Venous Excess Ultrasound (VExUS): Image Acquisition and Interpretation

Published on: May 16, 2025

895
Echocardiographic Assessment Using Subxiphoid-Only Examination for Hypotensive Patients
08:37

Echocardiographic Assessment Using Subxiphoid-Only Examination for Hypotensive Patients

Published on: April 18, 2025

356
Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
04:29

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

28.7K

Area of Science:

  • Hematology
  • Immunology
  • Genetics

Background:

  • VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome is a recently identified adult-onset autoinflammatory disorder.
  • It is characterized by somatic mutations in the UBA1 gene within hematopoietic stem and progenitor cells, leading to altered UBA1 isoform expression.

Purpose of the Study:

  • To elucidate the key features, pathogenesis, and clinical manifestations of VEXAS syndrome.
  • To enhance understanding for targeted treatment strategies and improve patient prognosis.

Main Methods:

  • Review of existing literature and clinical case data pertaining to VEXAS syndrome.
  • Analysis of the genetic basis (UBA1 mutations) and resulting pathobiology.

Main Results:

  • Somatic UBA1 mutations cause a shift in gene expression, leading to systemic inflammation and hematologic abnormalities.
  • Patients exhibit poor response to conventional immunosuppressants, with high-dose glucocorticoids offering limited efficacy.

Conclusions:

  • VEXAS syndrome is a severe, refractory condition with high mortality, necessitating increased physician awareness across specialties.
  • Further research into targeted therapies is crucial for improving outcomes in VEXAS syndrome patients.